Published in Cancer Weekly, February 24th, 1997
The unanimous decision, based upon a technical review by the Medical Policy Group, concluded that the increased effectiveness of the ThinPrep Pap Test leads to improved cervical cancer detection for its members.
"Providing a more effective Pap test to our female members is a fundamental part of our continuing commitment to women's healthcare," said Anne L. Meneghetti, M.D., Blue Cross Blue Shield. "Following a careful comparison of ThinPrep to existing cervical cancer screening...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.